Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05403177
Other study ID # MOHCCN-O
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date June 23, 2022
Est. completion date October 2026

Study information

Verified date June 2024
Source University Health Network, Toronto
Contact PM2C Central Office
Phone 416-946-4501
Email MOHCCN@uhn.ca
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The Marathon of Hope Cancer Centres Network (MOHCCN) is a national network of cancer centres that pursue collaborative cancer research in precision medicine (an emerging approach for disease treatment and prevention that considers individual variability in DNA, environment and lifestyle) to accelerate the discovery of innovations and improve the health outcomes for cancer patients


Description:

The purpose of this study is to use evolving technologies such as genomics and artificial intelligence to study cancer so that the right treatment can be given to the right patient, at the right time. Approximately 15,000 participants will take part in the greater MOHCCN study across Canada in the first 5 years, and ultimately the goal is to enroll up to 100,000 over next 10 years.


Recruitment information / eligibility

Status Recruiting
Enrollment 500
Est. completion date October 2026
Est. primary completion date October 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Patients with histological and cytological confirmation of blood or solid tumor malignancies. 2. All patients must be able to satisfy the required minimum data elements for the 15k gold standard cohort through: - existing data that satisfies the minimal requirements of a gold standard case, AND/OR - previously collected and sufficient biospecimens (tumor and/or blood samples) for whole-genome and transcriptome sequencing and immunophenotype characterization, AND/OR - new blood collection and/or tumor biopsy 3. Agrees to share anonymized clinical and genomic data. Exclusion Criteria: None.

Study Design


Locations

Country Name City State
Canada Princess Margaret Cancer Centre Toronto Ontario

Sponsors (4)

Lead Sponsor Collaborator
University Health Network, Toronto Ontario Institute for Cancer Research, Princess Margaret Hospital, Canada, Terry Fox Research Institute

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of patients included in a pan-Canadian cohort with comprehensive clinical and genomic data Consolidate and annotate data from patients included in a pan-Canadian cohort 5 years
Secondary Development of standard practices to create a unique shareable dataset of molecular, imaging, clinical and health outcome information on Canadian cancer cases Improve the cancer research paradigm by bringing teams or researchers together and leverage valuable information genomic and clinical data from Canadian cancer cases. 5 years
Secondary Clinical effectiveness and cost-effectiveness of precision cancer medicine to advance clinical implementation and reimbursement decisions Health technology assessment tools will be used to evaluate the real-world value of precision medicine 5 years
Secondary Development and collection of patient-reported outcomes to enhance patient-centeredness in precision cancer medicine Health technology assessment tools will be used to evaluate the real-world value of precision medicine 5 years
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2